Verici has now received Local Coverage for its post kidney transplant test Tutivia. A pivotal milestone that removes the uncertainty that has weighed so heavily on shares, and confirms that Verici is a commercial business with an exciting growth trajectory ahead. Importantly, Verici can now bill for historical and ongoing Tutivia test revenues, with Verici on track to deliver on our FY25E forecasts of $3.2m Tutivia revenues. Although, with Local Coverage now secured, we expect this to be a catal ....
